Calmodulin antagonist action in smooth-muscle myosin phosphorylation. Different mechanisms for trifluoperazine and calmidazolium inhibition

钙调蛋白拮抗剂在平滑肌肌球蛋白磷酸化中的作用。三氟拉嗪和钙咪唑抑制作用的不同机制。

阅读:1

Abstract

The mechanism of inhibition of myosin phosphorylation by calmodulin antagonists [trifluoperazine (TFP) and calmidazolium (CAL)] was investigated in two enzyme-substrate systems: (1) mixtures of isolated myosin phosphorylatable light-chain (L20), myosin light-chain kinase (MCLKase) and calmodulin (CM); (2) synthetic self-assembled myosin filaments containing tightly bound endogenous MLCKase and CM. Double-reciprocal plots obtained with the first system were non-linear, indicating that the antagonists did not act exclusively on CM to inhibit MLCKase. First-order phosphorylation progress curves obtained at different CM antagonist concentrations for the more native filamentous myosin system indicated that the antagonists could also inhibit phosphorylation by interaction with the myosin phosphorylation site. Further analysis of these data in accordance with Reiner [(1969) Behavior of Enzyme Systems, 2nd edn., pp. 185-201, Van Nostrand-Reinhold, New York] showed that over a range of concentrations required to inhibit phosphorylation TFP interacted with free CM as well as with the myosin phosphorylation site: accordingly inhibition was of an activator- and substrate-depletion type. CAL inhibition was more CM-specific and operated via an activator-combination mechanism, inhibiting free CM as well as the CM-MLCKase complex. Both CM and the isolated L20 light chain antagonized the inhibitory effects of CAL and TFP, consistent with the above analysis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。